Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?

Since December 2019, when the first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, SARS-CoV-2 has caused a global pandemic, with more than 75 million cases and over 1.6 million deaths worldwide (1). The international community has invested enormous resources in the devel...

Full description

Saved in:
Bibliographic Details
Published in:Croatian Medical Journal 2021, Vol.62 (1), p.95
Main Authors: Marčec, Robert, Likić, Robert
Format: Review
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 1
container_start_page 95
container_title Croatian Medical Journal
container_volume 62
creator Marčec, Robert
Likić, Robert
description Since December 2019, when the first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, SARS-CoV-2 has caused a global pandemic, with more than 75 million cases and over 1.6 million deaths worldwide (1). The international community has invested enormous resources in the development of safe and effective vaccines, which were registered and approved for widespread use in record time. Nevertheless, limited production capacities and vaccine hesitancy could impede a global post-COVID19 recovery, particularly in developing countries.
doi_str_mv 10.3325/cmj.2021.62.95
format review
fullrecord <record><control><sourceid>hrcak</sourceid><recordid>TN_cdi_hrcak_primary_oai_hrcak_srce_hr_278049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_hrcak_srce_hr_278049</sourcerecordid><originalsourceid>FETCH-hrcak_primary_oai_hrcak_srce_hr_2780493</originalsourceid><addsrcrecordid>eNqVis2OgjAYABuzJrLq1fP3ArD9AYSTB3SznkyM8Uoa_IgVaElbjL69JOsLeJrJZAhZMRoJwZOfqrtFnHIWpTzKkwkJ2JjDjKXpFwmoSESYJzSekW_nbpRyGsdpQI6FGdoL1O1wNw_ZKY3QIPZQHM77Lcuhl16h9g7M4MHUcDWuV162DqS-gNIetVN3hEpahEEr7zYLMq3HAZdvzkn4uzsVf-HVVrIpe6s6aZ-lkar8L85WOGrJ1xmNc_Hp_wI_Pk6u</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>review</recordtype></control><display><type>review</type><title>Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?</title><source>Open Access: PubMed Central</source><creator>Marčec, Robert ; Likić, Robert</creator><creatorcontrib>Marčec, Robert ; Likić, Robert</creatorcontrib><description>Since December 2019, when the first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, SARS-CoV-2 has caused a global pandemic, with more than 75 million cases and over 1.6 million deaths worldwide (1). The international community has invested enormous resources in the development of safe and effective vaccines, which were registered and approved for widespread use in record time. Nevertheless, limited production capacities and vaccine hesitancy could impede a global post-COVID19 recovery, particularly in developing countries.</description><identifier>ISSN: 0353-9504</identifier><identifier>EISSN: 1332-8166</identifier><identifier>DOI: 10.3325/cmj.2021.62.95</identifier><identifier>CODEN: CMEJEN</identifier><language>eng</language><publisher>Medicinski fakultet Sveučilišta u Zagrebu, Medicinski fakultet Sveučilišta u Splitu, Medicinski fakultet Sveučilišta u Rijeci</publisher><ispartof>Croatian Medical Journal, 2021, Vol.62 (1), p.95</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,313,776,780,788,881,27899,27902</link.rule.ids></links><search><creatorcontrib>Marčec, Robert</creatorcontrib><creatorcontrib>Likić, Robert</creatorcontrib><title>Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?</title><title>Croatian Medical Journal</title><description>Since December 2019, when the first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, SARS-CoV-2 has caused a global pandemic, with more than 75 million cases and over 1.6 million deaths worldwide (1). The international community has invested enormous resources in the development of safe and effective vaccines, which were registered and approved for widespread use in record time. Nevertheless, limited production capacities and vaccine hesitancy could impede a global post-COVID19 recovery, particularly in developing countries.</description><issn>0353-9504</issn><issn>1332-8166</issn><fulltext>true</fulltext><rsrctype>review</rsrctype><creationdate>2021</creationdate><recordtype>review</recordtype><recordid>eNqVis2OgjAYABuzJrLq1fP3ArD9AYSTB3SznkyM8Uoa_IgVaElbjL69JOsLeJrJZAhZMRoJwZOfqrtFnHIWpTzKkwkJ2JjDjKXpFwmoSESYJzSekW_nbpRyGsdpQI6FGdoL1O1wNw_ZKY3QIPZQHM77Lcuhl16h9g7M4MHUcDWuV162DqS-gNIetVN3hEpahEEr7zYLMq3HAZdvzkn4uzsVf-HVVrIpe6s6aZ-lkar8L85WOGrJ1xmNc_Hp_wI_Pk6u</recordid><startdate>20210225</startdate><enddate>20210225</enddate><creator>Marčec, Robert</creator><creator>Likić, Robert</creator><general>Medicinski fakultet Sveučilišta u Zagrebu, Medicinski fakultet Sveučilišta u Splitu, Medicinski fakultet Sveučilišta u Rijeci</general><scope>VP8</scope></search><sort><creationdate>20210225</creationdate><title>Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?</title><author>Marčec, Robert ; Likić, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hrcak_primary_oai_hrcak_srce_hr_2780493</frbrgroupid><rsrctype>reviews</rsrctype><prefilter>reviews</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marčec, Robert</creatorcontrib><creatorcontrib>Likić, Robert</creatorcontrib><collection>Hrcak: Portal of scientific journals of Croatia</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marčec, Robert</au><au>Likić, Robert</au><format>journal</format><genre>article</genre><ristype>GEN</ristype><atitle>Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?</atitle><jtitle>Croatian Medical Journal</jtitle><date>2021-02-25</date><risdate>2021</risdate><volume>62</volume><issue>1</issue><spage>95</spage><pages>95-</pages><issn>0353-9504</issn><eissn>1332-8166</eissn><coden>CMEJEN</coden><abstract>Since December 2019, when the first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, SARS-CoV-2 has caused a global pandemic, with more than 75 million cases and over 1.6 million deaths worldwide (1). The international community has invested enormous resources in the development of safe and effective vaccines, which were registered and approved for widespread use in record time. Nevertheless, limited production capacities and vaccine hesitancy could impede a global post-COVID19 recovery, particularly in developing countries.</abstract><pub>Medicinski fakultet Sveučilišta u Zagrebu, Medicinski fakultet Sveučilišta u Splitu, Medicinski fakultet Sveučilišta u Rijeci</pub><doi>10.3325/cmj.2021.62.95</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0353-9504
ispartof Croatian Medical Journal, 2021, Vol.62 (1), p.95
issn 0353-9504
1332-8166
language eng
recordid cdi_hrcak_primary_oai_hrcak_srce_hr_278049
source Open Access: PubMed Central
title Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A41%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hrcak&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Could%20fluvoxamine%20keep%20COVID19%20patients%20out%20of%20hospitals%20and%20intensive%20care%20units?&rft.jtitle=Croatian%20Medical%20Journal&rft.au=Mar%C4%8Dec,%20Robert&rft.date=2021-02-25&rft.volume=62&rft.issue=1&rft.spage=95&rft.pages=95-&rft.issn=0353-9504&rft.eissn=1332-8166&rft.coden=CMEJEN&rft_id=info:doi/10.3325/cmj.2021.62.95&rft_dat=%3Chrcak%3Eoai_hrcak_srce_hr_278049%3C/hrcak%3E%3Cgrp_id%3Ecdi_FETCH-hrcak_primary_oai_hrcak_srce_hr_2780493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true